February 16, 2026

Atamyo Therapeutics Announces the Dosing of a Fourth Patient with ATA-200 in an Ongoing LGMD-R5 Clinical Trial, Supported by CureSCG

Atamyo Therapeutics announces continued progress in its ongoing clinical trial of ATA-200, with the recent dosing of a fourth patient, marking an important milestone in the development of its gene therapy for γ-sarcoglycan related limb […]

Read more

February 03, 2026

Atamyo Therapeutics Announces First Three Patients Dosed with ATA-200 Gene Therapy in on-going LGMD-R5 Clinical Trial, and Extension of Partnership with the Dion Foundation

Evry, France and Boston, MA (February 3, 2026) – Atamyo Therapeutics and The Dion Foundation for Children with Rare Diseases, today announced the expansion of their partnership to support financing of the first-in-human clinical trial […]

Read more